Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
People infected with HIV may have low levels of the virus in their body, even if they are
taking HIV medications. This study will evaluate the safety, pharmacokinetics (PK) (which is
how the body interacts with drugs), and immune response to BMS-936559, a drug that will be
administered by an intravenous (IV) infusion, in HIV-infected people receiving combination
antiretroviral therapy (cART) who have viral load levels below the limit of detection.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)